Accessing Shelved Compounds Through the CTSA Pharmaceutical Assets Portal

2. CTSA PHARMACEUTICAL ASSETS PORTAL www.ctsapharmaportal.org Kate Marusina, Ph.D., MBA December 2009

8. Recent Number of NMEs Approved by FDA is Disappointing PhRMA R&D Productivity (Avg Annual R&D Spend Increase = 10.3%; ’90-’07) Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2008; CDER PhRMA R&D Spend (Billions of Dollars) Number of NME Approvals by FDA NMEs Approved

9. Research & Development Productivity Needs Attention The Challenge – 1 of 10 is Aspirational!

10. …… ..but Opportunities to Improve Abound Preclinical Phase 1 Phase 2/ PoC Phase 3 Approval 65 55 25 65 85 Cumulative = 5% “ In times of profound change, the learners inherit the earth, while the learned find themselves beautifully equipped to deal with a world that no longer exists.” “ It still holds true that man is most uniquely human when he turns obstacles into opportunities.” - Eric Hoffer Stage % Survival versus

16. Two ways to create a match between Academia and Pharma

18. How to join the Portal (www.ctsapharmaportal.org)

19. Members of the Portal (as of June 09)

22. Specific target/disease interests (~150)

23. Two ways to create a match between Academia and Pharma

24. From Pharma to CTSA via FoX target Disease A Disease A Disease C Disease B Disease D Disease B

26. Data cloud for a target X

28. Example of a Filter